SGLT2抑制剂治疗炎症性肠病机制的研究进展

Research progress on the mechanism of SGLT2 inhibitors in the treatment of inflammatory bowel disease

炎症性肠病(inflammatory bowel disease,IBD)是一种病因未明的慢性肠道炎症性疾病,其病程受环境、遗传、免疫和微生物等多因素影响。目前,IBD具有治疗费用昂贵、治疗药物长期使用不良反应多或治疗不耐受等问题,迫切需要新的治疗选择。最新研究发现,新型降糖药钠-葡萄糖共转运体-2抑制剂(sodium-glucose cotransporter 2 inhibitors,SGLT2i)可能通过葡萄糖依赖性和非依赖性途径,延缓IBD进程。SGLT2i在降低炎症反应、提高先天免疫反应、抗氧化应激、减少细胞凋亡、增强细胞自噬诱导以及调节肠道菌群失衡等方面的研究进展,揭示了SGLT2i具有治疗IBD的潜力。

Inflammatory bowel disease(IBD)is a chronic inflammatory disease of intestinal tract with an elusive etiology.Its clinical course is influenced by a large variety of environmental,genetic,immunologic and microbiologic factors.Currently IBD has outstanding problems of high expenses,many adverse reactions from long-term use of therapeutic drugs and treatment intolerance.There is an urgent need for formulating novel therapeutic options.Recent studies have demonstrated that hypoglycemic agent sodium-glucose cotransporter-2 inhibitor(SGLT2i)could delay the progression of IBD through glucose-dependent and independent pathways.It was capable of attenuating inflammatory responses,ameliorating innate immune responses,antagonizing oxidative stress,arresting apoptosis,enhancing autophagy induction and regulating intestinal microbiota imbalance in IBD.